Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | GBA1 | P04062 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16997066 | 0.86 | PIK3CD (0.39) | PIK3CDPDE4D | |
| SCHEMBL18860301 | 0.86 | PIK3CD (0.44) | PIK3CDDAO | |
| SCHEMBL766688 | 0.86 | PIK3CD (0.39) | PIK3CDPDE4D | |
| SCHEMBL23265408 | 0.85 | PIK3CD (0.42) | PIK3CDDAO | |
| SCHEMBL30837730 | 0.82 | PIK3CD (0.35) | PIK3CDDAO | |
| SCHEMBL2201094 | 0.82 | PIK3CD (0.35) | PIK3CDDAO | |
| SCHEMBL22458613 | 0.82 | PIK3CD (0.35) | PIK3CDDAO | |
| SCHEMBL1678779 | 0.82 | — | — | |
| SCHEMBL19939298 | 0.80 | PIK3CD (0.34) | PIK3CDDAOPDE4D | |
| SCHEMBL19231429 | 0.80 | PIK3CD (0.39) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024086814-A2 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20230357179-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-11-09 | — | — | US | disclosed |
| US-20230357179-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-11-09 | — | — | US | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-11744825-B2 | Methods of treating hypersensitive cough or itching using ion channel inhibitory compounds | AFASCI, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11718613-B2 | N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-08-08 | — | — | US | disclosed |
| WO-2023108103-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023108108-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230140430-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2023-05-04 | — | — | US | disclosed |
| US-8518934-B2 | Oxycarbamoyl compounds and the use thereof | SHONOGI & CO., LTD. (JP) | 2013-08-27 | — | — | US | disclosed |
| US-20130102586-A1 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2013-04-25 | — | — | US | disclosed |
| US-20120190688-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BRUNCKO MILAN (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20110124628-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110098276-A1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2011-04-28 | — | — | US | disclosed |
| US-7615651-B2 | Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof | PFIZER INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-7615651-B2 | Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof | PFIZER INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-20080167371-A1 | Diaryl, Dipyridinyl and Aryl-Pyridinyl Derivatives and Uses Thereof | PFIZER INC. | 2008-07-10 | — | — | US | disclosed |
| US-20080167371-A1 | Diaryl, Dipyridinyl and Aryl-Pyridinyl Derivatives and Uses Thereof | PFIZER INC. | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | PIK3CD 2563/4885DAO 3606/4885KDM1A 3304/4885 |
| US-11744825-B2 | Methods of treating hypersensitive cough or itching using ion channel inhibitory compounds | TRPV1, TRPA1, TRPV2 | PIK3CD 2392/4885DAO 1653/4885KDM1A 3640/4885 |
| US-20110098276-A1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | CACNA1B, ORAI1, CACNA1I | PIK3CD 2783/4885DAO 1078/4885KDM1A 2004/4885 |
| US-20230357179-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | PIK3CD 512/4885DAO 2629/4885KDM1A 2074/4885 |
| US-11718613-B2 | N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors | BCL2A1, BCL3, BCL2 | PIK3CD 4257/4885DAO 4192/4885KDM1A 787/4885 |
| US-20230140430-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | TLR7, TLR1, TLR9 | PIK3CD 1225/4885DAO 1208/4885KDM1A 1414/4885 |
| US-20080167371-A1 | Diaryl, Dipyridinyl and Aryl-Pyridinyl Derivatives and Uses Thereof | OPRD1, OPRK1, OPRL1 | PIK3CD 3397/4885DAO 482/4885KDM1A 1250/4885 |
| US-20120190688-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | PIK3CD 2110/4885DAO 3726/4885KDM1A 4155/4885 |
| US-20110124628-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | PIK3CD 2110/4885DAO 3726/4885KDM1A 4155/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | PIK3CD 1645/4885DAO 1329/4885KDM1A 691/4885 |
| US-20130102586-A1 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MAP3K9, MAP3K19, MAP4K2 | PIK3CD 298/4885DAO 2148/4885KDM1A 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.